Literature DB >> 17177034

[Angina pectoris and ST-elevation after chemotherapy with 5-fluorouracil].

S Spencker1, A Schmittel, D Westermann, A Marek, H P Schultheiss, B Witzenbichler.   

Abstract

We report on the case of a 64 year old male who received chemotherapy for a metastatic squamous cell carcinoma of the oropharynx. The chemotherapeutic regimen consisted of 5-fluorouracil (5-FU) and cisplatin. Six hours after completion of the first 24 h continuous infusion of 5-FU, the patient developed severe chest pain accompanied by vegetative symptoms and a pronounced ST-elevation of the precordial leads. Under the suspicion of an acute anterior myocardial infarction an immediate coronary angiogram was performed, demonstrating a total occlusion of the left anterior descending (LAD) coronary artery close to the left main stem. The other coronary arteries appeared smooth. After the intracoronary administration of nitroglycerine, the LAD reopened spontaneously without any residual stenosis, paralleled by complete relief of all symptoms. Therefore, 5-FU induced coronary spasm was diagnosed. After initial therapy with intravenous nitrate followed by oral calcium channel blocker, the patient remained free of symptoms and no rise in cardiac enzymes were noted. The chemotherapeutic regimen was changed to cisplatin plus docetaxel. No new attacks of chest pain occurred and the antivasospastic therapy could be stopped without further events.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17177034     DOI: 10.1007/s00108-006-1750-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  14 in total

Review 1.  5-Fluorouracil cardiotoxicity: a critical review.

Authors:  W J Gradishar; E E Vokes
Journal:  Ann Oncol       Date:  1990-11       Impact factor: 32.976

2.  Coronary artery spasm induced by 5-fluorouracil.

Authors:  P Alter; M Herzum; J R Schaefer; B Maisch
Journal:  Z Kardiol       Date:  2005-01

Review 3.  Cardiotoxicity of the antiproliferative compound fluorouracil.

Authors:  K Becker; J F Erckenbrecht; D Häussinger; T Frieling
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

Review 4.  Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.

Authors:  A F Sobrero; C Aschele; J R Bertino
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

5.  Clinical cardiotoxicity of 5-fluorouracil.

Authors:  D L Keefe; N Roistacher; M K Pierri
Journal:  J Clin Pharmacol       Date:  1993-11       Impact factor: 3.126

Review 6.  Fluorouracil cardiotoxicity.

Authors:  A J Anand
Journal:  Ann Pharmacother       Date:  1994-03       Impact factor: 3.154

7.  In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle.

Authors:  M Mosseri; H J Fingert; L Varticovski; S Chokshi; J M Isner
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

8.  Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.

Authors:  M de Forni; M C Malet-Martino; P Jaillais; R E Shubinski; J M Bachaud; L Lemaire; P Canal; C Chevreau; D Carrié; P Soulié
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

9.  Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy -- a survey of 427 patients.

Authors:  Nicolas Tsavaris; Christos Kosmas; Maria Vadiaka; Michalis Efremidis; Andreas Zinelis; Dimitris Beldecos; Dimitris Sakelariou; Christos Koufos; George Stamatelos
Journal:  Med Sci Monit       Date:  2002-06

Review 10.  Cardiotoxicity of cytotoxic drugs.

Authors:  Kirsten J M Schimmel; Dick J Richel; Renée B A van den Brink; Henk-Jan Guchelaar
Journal:  Cancer Treat Rev       Date:  2004-04       Impact factor: 12.111

View more
  1 in total

Review 1.  5-fluorouracil and cardiotoxicity: a review.

Authors:  Jaskanwal D Sara; Jasvinder Kaur; Ryan Khodadadi; Muneeb Rehman; Ronstan Lobo; Sakti Chakrabarti; Joerg Herrmann; Amir Lerman; Axel Grothey
Journal:  Ther Adv Med Oncol       Date:  2018-06-18       Impact factor: 8.168

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.